| 1 |
van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer[J]. Lancet 2011, 378(9804): 1741-1755.
|
| 2 |
Higgins KA, Gorgens S, Sudmeier LJ, et al. Recent developments in limited stage small cell lung cancer[J]. Transl Lung Cancer Res, 2019, 8(Suppl 2): S147-S152.
|
| 3 |
Schreiber D, Rineer J, Weedon J, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated?[J] Cancer, 2010, 116(5): 1350-1357.
|
| 4 |
Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer[J]. Transl Lung Cancer Res 2018, 7(1): 69-79.
|
| 5 |
Ganti AKP, Loo BW, Bassetti M, et al. Small cell lung cancer, Version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw 2021, 19(12): 1441-1464.
|
| 6 |
Yang CF, Chan DY, Speicher PJ, et al. Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer[J]. J Clin Oncol 2016, 34(10): 1057-1064.
|
| 7 |
Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer[J]. N Engl J Med, 1992, 327(23):1618-1624.
|
| 8 |
Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104[J]. J Clin Oncol, 2002, 20(14):3054-3060.
|
| 9 |
Varlotto JM, Recht A, Flickinger JC, et al. Lobectomy leads to optimal survival in early-stage small cell lung cancer: a retrospective analysis[J]. J Thorac Cardiovasc Surg, 2011, 142(3):538-546.
|
| 10 |
Combs SE, Hancock JG, Boffa DJ, et al. Bolstering the case for lobectomy in stages I, II, and IIIA small-cell lung cancer using the National Cancer Data Base[J]. J Thorac Oncol, 2015, 10(2): 316-323.
|
| 11 |
Cheng Y, Han L, Wu L, et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: The ASTRUM-005 randomized clinical trial[J]. JAMA 2022, 328(12): 1223-1232.
|
| 12 |
Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)[J]. J Clin Oncol, 2021, 39(6):619-630.
|
| 13 |
Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN[J]. ESMO Open, 2022, 7(2): 100408.
|
| 14 |
陈克能. 小细胞肺癌的外科治疗需要重新审视[J]. 中国胸心血管外科临床杂志, 2021, 28(11): 1261-1266.
|
| 15 |
Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group[J]. J Clin Oncol, 2008, 26(21):3552-3559.
|
| 16 |
Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer[J]. N Engl J Med, 1994, 330(3): 153-158.
|
| 17 |
Duan H, Shi L, Shao C, et al. A multicenter, single-arm, open study of neoadjuvant or conversion atezolizumab in combination with chemotherapy in resectable small cell lung cancer (Cohort Study)[J]. Int J Surg, 2023, 109(9): 2641-2649.
|
| 18 |
Lu M, Zhang R, Qi LS, et al. Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited-stage small-cell lung cancer[J]. Thorac Cancer, 2022, 13(22): 3208-3216.
|
| 19 |
Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(11): 1413-1422.
|
| 20 |
Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer[J]. N Engl J Med 2018, 378(21):1976-1986.
|